Interventional study for severe obesity patients with non-alcoholic fatty liver disease (NAFLD) by Mazindol

Interventional study for severe obesity patients with non-alcoholic fatty liver disease (NAFLD) by Mazindol - Interventional study for severe obesity with NAFLD by Mazindol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022879

Enrollment

Registered

2016-07-01

Start date

2016-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe obesity patient with non-alcoholic fatty liver disease

Interventions

12 weeks, Mazindol 1.5 mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with BMI above 35 and NAFLD diagnosed with the NAFLD guideline 2010

Exclusion criteria

Exclusion criteria: Allergy to Mazindol, Glaucoma, Severe heart disease, Severe diabetes mellitus, Severe liver and renal disturbance, Severe hypertension, Cerebrovascular disease, Mental illness, Seizure, Alcohol and drug abuse, MAO inhibitor, Pregnant woman

Design outcomes

Primary

Measure	Time frame
Improvement in body weight 12 weeks after administration	—

Secondary

Measure	Time frame
Improvement in liver function 12 weeks after administration	—

Countries

Japan

Contacts

Public ContactYasuyo Nakajima

Gunma University Hospital Endocrinology and Diabates

ynihei@gunma-u.ac.jp027-220-8122

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026